Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Return on Capital Employed: 2018-2019

Historic Return on Capital Employed for Monopar Therapeutics (MNPR) over the last 2 years, with Dec 2019 value amounting to -0.51%.

  • Monopar Therapeutics' Return on Capital Employed fell 7.00% to -0.51% in Q4 2019 from the same period last year, while for Dec 2019 it was -0.51%, marking a year-over-year decrease of 7.00%. This contributed to the annual value of -0.45% for FY2019, which is 4.00% down from last year.
  • Monopar Therapeutics' Return on Capital Employed amounted to -0.51% in Q4 2019, which was up 38.52% from -0.83% recorded in Q3 2019.
  • Over the past 5 years, Monopar Therapeutics' Return on Capital Employed peaked at -0.38% during Q3 2018, and registered a low of -2.03% during Q2 2018.
  • Moreover, its 2-year median value for Return on Capital Employed was -0.65% (2019), whereas its average is -0.92%.
  • The largest annual percentage gain for Monopar Therapeutics' Return on Capital Employed in the last 5 years was 132bps (2019), contrasted with its biggest fall of 45bps (2019).
  • Over the past 2 years, Monopar Therapeutics' Return on Capital Employed (Quarterly) stood at -0.44% in 2018, then decreased by 7bps to -0.51% in 2019.
  • Its Return on Capital Employed was -0.51% in Q4 2019, compared to -0.83% in Q3 2019 and -0.71% in Q2 2019.